Filing Flows › Neuronetics (STIM) › Q3 2026 › vs Q3 2025
Neuronetics (STIM) Q3 2026 vs Q3 2025 (year over year)
Neuronetics's revenue rose $4.7M (+13%) from $37.3M in Q3 2025 to $42.0M in Q3 2026. The biggest changes: Service +$4.4M (+20%); NeuroStar +$281K (+2%).
Neuronetics, Q3 2026: revenue $42.0M (+12% year over year), operating margin 1.3%, net loss $1.6M, operating cash flow $1.2M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.8% | -2.4% | +4.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Service | $26.2M | $21.8M | $4.4M | +20% |
| NeuroStar | $15.8M | $15.5M | $281K | +2% |
| Revenue | $42.0M | $37.3M | $4.7M | +13% |
| Net loss | $1.6M | $9.4M | −$7.8M | -83% |
| Costs & expenses | $43.5M | $46.7M | −$3.2M | -7% |
| Operating costs | $41.4M | $44.6M | −$3.2M | -7% |
| Interest & other, net | $2.1M | $2.1M | $17K | +0.8% |
| Cost of revenue | $20.1M | $20.2M | −$117K | -0.6% |
| Research & development | $1.2M | $1.5M | −$314K | -21% |
| Sales & marketing | $8.5M | $11.8M | −$3.4M | -28% |
| General & admin | $11.7M | $11.1M | $598K | +5% |
| Operating cash sources | $2.8M | $8.6M | −$5.8M | -68% |
| Depreciation & amortization | $742K | $886K | −$144K | -16% |
| Share-based compensation | $178K | $1.4M | −$1.2M | -87% |
| Working capital & other | $1.9M | $6.3M | −$4.4M | -70% |
| Net loss absorbed | $1.6M | $9.4M | −$7.8M | -83% |
| Operating cash flow | $1.2M | −$785K | $2.0M | — |
| Free cash flow (OCF − capex) | $768K | −$899K | $1.7M | — |
| Capital expenditures | $470K | $114K | $356K | +312% |
Questions
How much did Neuronetics's revenue grow year over year in Q3 2026?
Neuronetics's revenue rose $4.7M (+13%) from $37.3M in Q3 2025 to $42.0M in Q3 2026.
What drove Neuronetics's revenue change in Q3 2026?
Service +$4.4M (+20%); NeuroStar +$281K (+2%).